GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: BMC Cell Biology, Springer Science and Business Media LLC, Vol. 12, No. 1 ( 2011-12)
    Abstract: Aurora kinases and loss of p53 function are implicated in the carcinogenesis of aneuploid esophageal cancers. Their association with occurrence of multipolar mitoses in the two main histotypes of aneuploid esophageal squamous cell carcinoma (ESCC) and Barrett's adenocarcinoma (BAC) remains unclear. Here, we investigated the occurrence of multipolar mitoses, Aurora-A/-B gene copy numbers and expression/activation as well as p53 alterations in aneuploid ESCC and BAC cancer cell lines. Results A control esophageal epithelial cell line (EPC-hTERT) had normal Aurora-A and -B gene copy numbers and expression, was p53 wild type and displayed bipolar mitoses. In contrast, both ESCC (OE21, Kyse-410) and BAC (OE33, OE19) cell lines were aneuploid and displayed elevated gene copy numbers of Aurora-A (chromosome 20 polysomy: OE21, OE33, OE19; gene amplification: Kyse-410) and Aurora-B (chromosome 17 polysomy: OE21, Kyse-410). Aurora-B gene copy numbers were not elevated in OE19 and OE33 cells despite chromosome 17 polysomy. Aurora-A expression and activity (Aurora-A/phosphoT288) was not directly linked to gene copy numbers and was highest in Kyse-410 and OE33 cells. Aurora-B expression and activity (Aurora-B/phosphoT232) was higher in OE21 and Kyse-410 than in OE33 and OE19 cells. The mitotic index was highest in OE21, followed by OE33 〉 OE19 〉 Kyse-410 and EPC-hTERT cells. Multipolar mitoses occurred with high frequency in OE33 (13.8 ± 4.2%), followed by OE21 (7.7 ± 5.0%) and Kyse-410 (6.3 ± 2.0%) cells. Single multipolar mitoses occurred in OE19 (1.0 ± 1.0%) cells. Distinct p53 mutations and p53 protein expression patterns were found in all esophageal cancer cell lines, but complete functional p53 inactivation occurred in OE21 and OE33 only. Conclusions High Aurora-A expression alone is not associated with overt multipolar mitoses in aneuploid ESCC and BAC cancer cells, as specifically shown here for OE21 and OE33 cells, respectively. Additional p53 loss of function mutations are necessary for this to occur, at least for invasive esophageal cancer cells. Further assessment of Aurora kinases and p53 interactions in cells or tissue specimens derived from non-invasive dysplasia (ESCC) or intestinal metaplasia (BAC) are necessary to disclose a potential causative role of Aurora kinases and p53 for development of aneuploid, invasive esophageal cancers.
    Type of Medium: Online Resource
    ISSN: 1471-2121
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2011
    detail.hit.zdb_id: 2964981-X
    detail.hit.zdb_id: 2041486-9
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 111, No. 5 ( 2008-03-01), p. 2909-2918
    Abstract: Gastrointestinal graft-versus-host disease (GVHD) is a common and potentially life-threatening complication after allogeneic hematopoietic stem-cell transplantation (HSCT). Noninvasive tests for assessment of GVHD activity are desirable but lacking. In the present study, we were able to visualize intestinal GVHD-associated inflammation in an allogeneic murine transplantation model by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in vivo. A predominant localization of intestinal GVHD to the colon was verified by histology and fluorescence reflectance imaging of enhanced green fluorescent protein (EGFP)–expressing donor cells. Colonic infiltration by EGFP+ donor lymphocytes matched increased FDG uptake in PET examinations. These preclinical data were prospectively translated into 30 patients with suspected intestinal GVHD beyond 20 days after transplantation. A total of 14 of 17 patients with a diagnostic histology showed significant FDG uptake of the gut, again predominantly in the colon. No increased FDG uptake was detected in 13 patients without histologic evidence of intestinal GVHD. Our findings indicate that FDG-PET is a sensitive and specific noninvasive imaging technique to assess intestinal GVHD, map its localization, and predict and monitor treatment responsiveness. Novel targeted tracers for PET may provide new insights into the pathophysiology of GVHD and bear the potential to further improve GVHD diagnosis.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2008
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal for ImmunoTherapy of Cancer, BMJ, Vol. 12, No. 2 ( 2024-02), p. e008155-
    Abstract: The antitumor activity of natural killer (NK) cells can be enhanced by specific targeting with therapeutic antibodies that trigger antibody-dependent cell-mediated cytotoxicity (ADCC) or by genetic engineering to express chimeric antigen receptors (CARs). Despite antibody or CAR targeting, some tumors remain resistant towards NK cell attack. While the importance of ICAM-1/LFA-1 interaction for natural cytotoxicity of NK cells is known, its impact on ADCC induced by the ErbB2 (HER2)-specific antibody trastuzumab and ErbB2-CAR-mediated NK cell cytotoxicity against breast cancer cells has not been investigated. Methods Here we used NK-92 cells expressing high-affinity Fc receptor FcγRIIIa in combination with trastuzumab or ErbB2-CAR engineered NK-92 cells (NK-92/5.28.z) as well as primary human NK cells combined with trastuzumab or modified with the ErbB2-CAR and tested cytotoxicity against cancer cells varying in ICAM-1 expression or alternatively blocked LFA-1 on NK cells. Furthermore, we specifically stimulated Fc receptor, CAR and/or LFA-1 to study their crosstalk at the immunological synapse and their contribution to degranulation and intracellular signaling in antibody-targeted or CAR-targeted NK cells. Results Blockade of LFA-1 or absence of ICAM-1 significantly reduced cell killing and cytokine release during trastuzumab-mediated ADCC against ErbB2-positive breast cancer cells, but not so in CAR-targeted NK cells. Pretreatment with 5-aza-2'-deoxycytidine induced ICAM-1 upregulation and reversed NK cell resistance in ADCC. Trastuzumab alone did not sufficiently activate NK cells and required additional LFA-1 co-stimulation, while activation of the ErbB2-CAR in CAR-NK cells induced efficient degranulation independent of LFA-1. Total internal reflection fluorescence single molecule imaging revealed that CAR-NK cells formed an irregular immunological synapse with tumor cells that excluded ICAM-1, while trastuzumab formed typical peripheral supramolecular activation cluster (pSMAC) structures. Mechanistically, the absence of ICAM-1 did not affect cell–cell adhesion during ADCC, but rather resulted in decreased signaling via Pyk2 and ERK1/2, which was intrinsically provided by CAR-mediated targeting. Furthermore, while stimulation of the inhibitory NK cell checkpoint molecule NKG2A markedly reduced FcγRIIIa/LFA-1-mediated degranulation, retargeting by CAR was only marginally affected. Conclusions Downregulation of ICAM-1 on breast cancer cells is a critical escape mechanism from trastuzumab-triggered ADCC. In contrast, CAR-NK cells are able to overcome cancer cell resistance caused by ICAM-1 reduction, highlighting the potential of CAR-NK cells in cancer immunotherapy.
    Type of Medium: Online Resource
    ISSN: 2051-1426
    Language: English
    Publisher: BMJ
    Publication Date: 2024
    detail.hit.zdb_id: 2719863-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Turkish Journal of Anaesthesiology and Reanimation, Galenos Yayinevi, Vol. 49, No. 6 ( 2021-12-27), p. 494-499
    Type of Medium: Online Resource
    URL: Issue
    Language: Unknown
    Publisher: Galenos Yayinevi
    Publication Date: 2021
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 112, No. 11 ( 2008-11-16), p. 4613-4613
    Abstract: Graft-versus-host disease (GvHD) is a common and potentially life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT). It is mediated by donor immune cells reacting against alloantigens presented by host or donor derived professional antigen presenting cells or expressed on host tissue. In addition, donor derived T-cells contribute to the beneficial graft-versus-tumor (GvT) reaction targeting minor histocompatibility antigens and, as previously demonstrated (Stelljes et al., Blood2004;104:1210-6), tumor associated antigens (TAAs). Several publications have shown that regulatory T-cells (Tregs) and mesenchymal stem cells (MSCs) can be used to prevent or treat GvHD. Since both cell populations react in a largely unspecific manner on alloantigen mediated immune responses, it remains a matter of debate whether intervention with these cell populations might interfere with GvT reactions directed against TAAs. In order to investigate the effects of MSCs and Tregs on GvHD and tumor specific GvT reactions, we used a murine parent-into-F1 transplant model. After total body irradiation with 9 Gy F1[BALB/c × C57BL/6] (CB6F1) mice were transplanted with parental bone marrow and splenocytes from C57BL/6 (B6) or BALB/c donors, respectively. Following transplantation, CB6F1 recipients received either three doses of 1×106 MSCs of B6 or BALB/c origin s.c. within the first two weeks or 1×106 Tregs together with the transplant. To evaluate TAA specific GvT effects, transplanted recipients were inoculated with tumor cells sharing the MHC background of the donor strain. GvHD score and tumor size were monitored every other day. Treatment with unstimulated MSCs of B6 origin had only marginal effects on GvHD intensity. In contrast, mice treated with unstimulated MSCs of BALB/c origin or BL/6 MSCs stimulated in vitro with supernatant of allogeneic mixed lymphocyte cultures, showed no signs of GvHD like weight loss or skin damage. TAA specific GvT reactions were significantly impaired by MSCs of either origin resulting in markedly increased tumor growth. Analysis of in vivo primed T cells 25 days after transplantation by IFN-γ ELIspot assay revealed significantly reduced TAA specific T-cells in recipients treated with MSCs as compared to transplanted tumor bearing control animals. In our experimental setting, Tregs also reduced GvHD compared with transplanted controls. Again, specific immune responses targeting TAAs were also abolished. In conclusion, cellular immune modulation using MSCs or Tregs might be effective to modulate GvHD. However, both strategies clearly impair tumor specific GvT reactions in our experimental setting suggesting that these interventions might bear the risk of higher relapse rates after allogeneic HSCT. The different effects on GvHD by stimulated and unstimulated MSCs of B6 or BALB/c origin are being explored.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2008
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 3249-3249
    Abstract: Cell mediated GvT effects after allogeneic stem cell transplantation are heterogeneous with respect to effector cell populations, target antigens and their interrelation with graft-versus-host disease (GvHD). Mutated tumor-associated antigens (TAAs), as well as selectively or aberrantly expressed nonmutated antigens, represent potential targets for T cell-mediated GvT effects that are in principle separable from the generalized graft-versus-host reaction targeting widely expressed MHC alloantigens and mHAg. So far, it remains a matter of debate whether alloantigens ubiquitary expressed on tumor cells and normal host tissue are relevant targets of GvT responses. Methods To evaluate the role of MHC class I molecules and mHAg as targets for GvT reactions, we employed three different allogeneic parent-into-F1 murine transplant models (BALB/c [H-2d] or C57BL/6 [H-2b] → F1[BALB/c x C57BL/6] [H-2b/d] and BALB/c → F1[BALB/c x CBA/J] [H-2d/k] ). As previously shown, these transplant models allow for separate variation in the histocompatibility between donor cells and normal host tissue on the one hand and between donor cells and tumor tissue on the other hand. Test tumors were the donor derived myeloma / leukemia cell lines MPC11 [H-2d] and C1498 [H-2b] , which were stably transfected with MHC class I molecules H-2Kb, H-2Kd, H-2Kk or with the mHAg UTY. Results Compared with non-GvHD controls (F1[H-2b/d] mice transplanted with allogeneic bone marrow cells from BALB/c [H-2d] alone), significant GvT effects against the BALB/c derived tumor MPC11 occurred in F1[H-2b/d] recipients with severe GvHD (transplanted with bone marrow and additional splenic lymphocytes from BALB/c). Identical histocompatibility antigens of donor and tumor cells precluded allorecognition of tumor cells, leaving TAAs the only possible target antigens in this particular setting, with GvHD as a driving force for augmentation of tumor specific immune responses. The MPC11 myeloma [H-2d] , stably transfected with the C57BL/6 derived MHC class I molecule H-2Kb (MPC11-Kb), showed similar tumor growth compared to the wild type MPC11 in F1[H-2b/d] mice transplanted from BALB/c donors. Similar results could be observed with the C57BL/6 derived C1498 leukemia [H-2b] , transfected with the BALB/c MHC class I alloantigen H2Kd, in F1[H-2b/d] mice transplanted from C57BL/6 donors. In both experimental settings, the artificially expressed alloantigens H2Kb and H2Kd were also expressed ubiquitarily on tissues of F1[H-2b/d] recipients. In sharp contrast, MPC11 cells transfected with the CBA/J derived H2Kk (MPC11-Kk) alloantigen showed a significantly reduced tumor growth in F1[H-2b/d] recipients transplanted from BALB/c donors, demonstrating that MHC class I alloantigens are relevant targets, when expressed on tumors but not on healthy recipient tissue. Inoculation of MPC11-Kk in F1[H-2d/k] mice 3 or 7 days after transplantation from BALB/c donors showed a trend towards a reduced tumor growth compared to wild type MPC11 in recipients with severe GvHD. Later application of tumor cells (14 days after transplantation) showed similar growth pattern of both tumors, suggesting that MHC class I antigens might be GvT targets in the early phase after allogeneic transplantation. To evaluate the impact of ubiquitarily expressed mHAg, we established a C1498 cell line, which stably expressed UTY (C1498-UTY), a known immunogenic antigen of the male HY gene. In comparison with the wild type control, C1498-UTY showed similar tumor growth in male or female F1[H-2b/d] recipients, transplanted from naive female C57BL/6 donors. Immunization of female C57BL/6 donors with male splenocytes resulted in a significantly reduced tumor growth of the C1498-UTY in female F1[H-2b/d] recipients. In contrast, tumor growth of the UTY expressing and wild type C1498 was similar in male F1[H-2b/d] mice transplanted from immunized female C57BL/6 donors. Conclusion Our experimental data indicate that a biologically relevant GvT effect targeting MHC class I or mHAgs mainly occurs when these alloantigens are not ubiquitarily expressed, even in the context of severe GvHD. Consequently, TAAs and tissue- /hematopoietic specific antigens are most likely the main targets of GvT effects observed after allogeneic stem cell transplantation. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Bone Marrow Transplantation, Springer Science and Business Media LLC, Vol. 53, No. 7 ( 2018-7), p. 807-819
    Type of Medium: Online Resource
    ISSN: 0268-3369 , 1476-5365
    RVK:
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2018
    detail.hit.zdb_id: 2004030-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Immunity, Elsevier BV, Vol. 31, No. 5 ( 2009-11), p. 823-833
    Type of Medium: Online Resource
    ISSN: 1074-7613
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2009
    detail.hit.zdb_id: 2001966-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Molecular Microbiology, Wiley, Vol. 45, No. 3 ( 2002-07-25), p. 597-604
    Type of Medium: Online Resource
    ISSN: 0950-382X , 1365-2958
    Language: English
    Publisher: Wiley
    Publication Date: 2002
    detail.hit.zdb_id: 1501537-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Neuro-Oncology, Oxford University Press (OUP), ( 2023-05-06)
    Abstract: Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targeting HER2, which is expressed at elevated levels by a subset of glioblastomas. Methods Nine patients with recurrent HER2-positive GB were treated with single doses of 1 × 107, 3 × 107, or 1 × 108 irradiated CAR-NK cells injected into the margins of the surgical cavity during relapse surgery. Imaging at baseline and follow-up, peripheral blood lymphocyte phenotyping and analyses of the immune architecture by multiplex immunohistochemistry and spatial digital profiling were performed. Results There were no dose-limiting toxicities, and none of the patients developed a cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Five patients showed stable disease after relapse surgery and CAR-NK injection that lasted 7 to 37 weeks. Four patients had progressive disease. Pseudoprogression was found at injection sites in 2 patients, suggestive of a treatment-induced immune response. For all patients, median progression-free survival was 7 weeks, and median overall survival was 31 weeks. Furthermore, the level of CD8+ T-cell infiltration in recurrent tumor tissue prior to CAR-NK cell injection positively correlated with time to progression. Conclusions Intracranial injection of HER2-targeted CAR-NK cells is feasible and safe in patients with recurrent GB. 1 × 108 NK-92/5.28.z cells was determined as the maximum feasible dose for a subsequent expansion cohort with repetitive local injections of CAR-NK cells.
    Type of Medium: Online Resource
    ISSN: 1522-8517 , 1523-5866
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2023
    detail.hit.zdb_id: 2094060-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...